Initial public offerings are off to a bumpy start in 2022, evidenced by several delayed offerings and mixed performances among companies that have gone public amid choppy conditions, chilling the near-term outlook for IPO prospects. "There's been a significant rotation by investors out of growth and into value stocks, making IPOs less appealing right now," said Goodwin’s Life Sciences and Technology partner Ben Marsh, a former investment banker at Deutsche Bank. Read the Law360 article here.